From dopamine to salience to psychosis-linking biology, pharmacology and phenomenology of psychosis

Schizophrenia Research

Volumn 79, Issue 1, 2005, Pages 59-68

  Kapur, Shitij ^a,b   Mizrahi, Romina ^a   Li, Ming ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antipsychotics; Dopamine; Motivation; Psychosis; Salience

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHLORPROMAZINE; DOPAMINE; DOPAMINE RECEPTOR; HALOPERIDOL; METIROSINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ATTENUATION; AVOIDANCE BEHAVIOR; BIOLOGY; CLINICAL TRIAL; CONFERENCE PAPER; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG MECHANISM; DYSPHORIA; HUMAN; MOTIVATION; NONHUMAN; PHENOMENOLOGY; PREDICTION; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; REWARD; SIDE EFFECT; SYMPTOMATOLOGY;

ANTIPSYCHOTIC AGENTS; CHLORPROMAZINE; DOPAMINE; HUMANS; MOTIVATION; PSYCHOTIC DISORDERS; RECEPTORS, DOPAMINE D2;

EID: 25444483073     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2005.01.003     Document Type: Conference Paper

References (63)

1. 2 receptors by dopamine in schizophrenia Proc. Natl. Acad. Sci. U. S. A. 97 14 2000 8104 8109
2. O. Agid, S. Kapur, T. Arenovich, and R.B. Zipursky Delayed-onset hypothesis of antipsychotic action-a hypothesis tested and rejected Arch. Gen. Psychiatry 60 12 2003 1228 1235
3. M.A. Aguilar, M.I. Mari-Sanmillan, J.J. Morant-Deusa, and J. Minarro Different inhibition of conditioned avoidance response by clozapine and DA D1 and D2 antagonists in male mice Behav. Neurosci. 114 2 2000 389 400
4. H. Anisman, J. Irwin, R.M. Zacharko, and T.N. Tombaugh Effects of dopamine receptor blockade on avoidance performance: assessment of effects on cue-shock and response-outcome associations Behav. Neural Biol. 36 3 1982 280 290
5. A.G. Awad Subjective response to neuroleptics in schizophrenia Schizophr. Bull. 19 3 1993 609 618
6. A.G. Awad, and T.P. Hogan Subjective response to neuroleptics and the quality of life: implications for treatment outcome Acta Psychiatr. Scand., Suppl. 380 1994 27 32
7. A.G. Awad, and L.N. Voruganti Quality of life and new antipsychotics in schizophrenia. Are patients better off? Int. J. Soc. Psychiatry 45 4 1999 268 275
8. A.G. Awad, T.P. Hogan, L.N. Voruganti, and R.J. Heslegrave Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life Int. Clin. Psychopharmacol. 10 Suppl 3 1995 123 132
9. K.C. Berridge Pleasure, pain, desire and dread: hidden core processes of emotion D. Kahneman E. Diener N. Schwarz Well being: the foundations of hedonic psychology 1999 Russel Sage Foundation New York 525 557
10. K.C. Berridge, and T.E. Robinson What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res. Brain Res. Rev. 28 3 1998 309 369
11. G. Bignami Effects of neuroleptics, ethanol, hypnotic-sedatives, tranquilizers, narcotics, and minor stimulants in aversive paradigms G. Bignami Psychopharmacology of aversively motivated behavior 1978 Plenum New York 385 453
12. M.B. Bowers Jr. Pathogenesis of acute schizophrenic psychosis. An experimental approach Arch. Gen. Psychiatry 19 3 1968 348 355
13. J.F. Casey, I.F. Bennett, C.J. Lindley, L.E. Hollister, M.H. Gordon, and N.N. Springer Drug therapy in schizophrenia. A controlled study of the relative effectiveness of chlorpromazine, promazine, phenobarbital, and placebo Arch. Gen. Psychiatry 2 1960 210 220
14. J.F. Casey, J.J. Lasky, C.J. Klett, and L.E. Hollister Treatment of schizophrenic reactions with phenothiazine derivatives. A comparative study of chlorpromazine, triflupromazine, mepazine, prochlorperazine, perphenazine, and phenobarbital Am. J. Psychiatry 117 1960 97 105
15. E. Ceskova, and J. Svestka Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses Pharmacopsychiatry 26 4 1993 121 124
16. G. Chouinard, and R. Miller A rating scale for psychotic symptoms (RSPS): Part I. Theoretical principles and subscale 1: perception symptoms (illusions and hallucinations) Schizophr. Res. 38 2-3 1999 101 122
17. D.E. Clody, and P.L. Carlton Stimulus efficacy, chlorpromazine, and schizophrenia Psychopharmacology 69 2 1980 127 131
18. J. Delay, P. Deniker, and J.M. Harl Therapeutic method derived from hiberno-therapy in excitation and agitation states Ann. Med. Psychol. (Paris) 110 2:2 1952 267 273
19. R. Diamond Drugs and the quality of life: the patient's point of view J. Clin. Psychiatry 46 5 Pt 2 1985 29 35
20. J. Elkes, and C. Elkes Effect of chlorpromazine on the behaviour of chronically overactive psychotic patients Br. Med. J. 2 1954 560 565
21. H.C. Fibiger, and A.G. Phillips Reward, motivation, cognition: psychobiology of mesotelencephalic dopamine systems V.B. Mountcastle Handbook of physiology-the nervous system vol. 4 1986 American Physiological Society Bethesda, MD 647 675
22. H.C. Fibiger, A.P. Zis, and A.G. Phillips Haloperidol-induced disruption of conditioned avoidance responding: attenuation by prior training or by anticholinergic drugs Eur. J. Pharmacol. 30 2 1975 309 314
23. G.O. Gabbard Mind and brain in psychiatric treatment Bull. Menninger Clin. 58 4 1994 427 446
24. J. Gerlach, and E.B. Larsen Subjective experience and mental side-effects of antipsychotic treatment Acta Psychiatr. Scand., Suppl. 395 1999 113 117
25. P.L. Gilbert, M.J. Harris, L.A. McAdams, and D.V. Jeste Neuroleptic withdrawal in schizophrenic patients. A review of the literature Arch. Gen. Psychiatry 52 3 1995 173 188
26. S.N. Haber The primate basal ganglia: parallel and integrative networks J. Chem. Neuroanat. 26 4 2003 317 330
27. A. Heinz Anhedonia-a general nosology surmounting correlate of a dysfunctional dopaminergic reward system? Nervenarzt 70 5 1999 391 398
28. T.P. Hogan, and A.G. Awad Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures Psychol. Med. 22 2 1992 347 352
29. E.C. Johnstone, T.J. Crow, C.D. Frith, M.W. Carney, and J.S. Price Mechanism of the antipsychotic effect in the treatment of acute schizophrenia Lancet 1 8069 1978 848 851
30. O. Kampman, K. Lehtinen, V. Lassila, E. Leinonen, O. Poutanen, and A. Koivisto Attitudes towards neuroleptic treatment: reliability and validity of the attitudes towards neuroleptic treatment (ANT) questionnaire Schizophr. Res. 45 3 2000 223 234
31. S. Kapur Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia Am. J. Psychiatr. 160 1 2003 13 23
32. S. Kapur How antipsychotics become anti-'psychotic'-from dopamine to salience to psychosis Trends Pharmacol. Sci. 25 8 2004 402 406
33. S. Kapur, and D. Mamo Half a century of antipsychotics and still a central role for dopamine D2 receptors Prog. Neuro-Psychopharmacol. Biol. Psychiatry 27 7 2003 1081 1090
34. S. Kapur, and P. Seeman Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis Am. J. Psychiatry 158 3 2001 360 369
35. S. Kapur, T. Arenovich, O. Agid, R. Zipursky, S. Lindborg, and B. Jones Immediate onset of the anti-psychotic effect: the early onset hypothesis Am. J. Psychiatry 2005 (May)
36. K.S. Kendler A psychiatric dialogue on the mind-body problem Am. J. Psychiatry 158 7 2001 989 1000
37. H. Laborit, and P. Huguenard L' hibernation artificielle par moyen pharmacodynamique et physisques Presse Med. 59 1951 1321
38. S. Leucht The early onset of antipsychotic effect-a hypothesis tested, confirmed and extended 43rd Annual Meeting of the American College of Neuropsychopharmacology, Puerto Rico, ANCP Inc. 2004
39. D.A. Lewis, and P. Levitt Schizophrenia as a disorder of neurodevelopment Annu. Rev. Neurosci. 25 5 2002 409 432
40. M. Li, J. Parkes, P.J. Fletcher, and S. Kapur Evaluation of the motor initiation hypothesis of APD-induced conditioned avoidance decreases Pharmacol. Biochem. Behav. 78 4 2004 811 819
41. M. Li, P. Davidson, R. Budin, S. Kapur, and A.S. Fleming Effects of typical and atypical antipsychotic drugs on maternal behavior in postpartum female rats Schizophr. Res. 70 1 2004 69 80
42. H.Y. Meltzer The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics J. Clin. Psychopharmacol. 15 1 Suppl 1 1995 2S 3S (Feb)
43. R. Miller The time course of neuroleptic therapy for psychosis: role of learning processes and implications for concepts of psychotic illness Psychopharmacology 92 4 1987 405 415
44. R. Miller Hyperactivity of associations in psychosis Aust. N. Z. J. Psychiatry 23 2 1989 241 248
45. Mizrahi, R., Bagby, M., Zipursky, R., Kapur, S., in press. How antipsychotics work: the patients' perspective. Progress in Neuropsychopharmacology. in press.
46. P.E.M. Phillips, G.D. Stuber, M.L.A.V. Heien, R.M. Wightman, and R.M. Carelli Subsecond dopamine release promotes cocaine seeking Nature 422 6932 2003 614 618
47. D. Ponsluns An analysis of chlorpromazine-induced suppression of the avoidance response Psychopharmacologia 3 1962 361 373
48. G. Roberts The origins of delusion Br. J. Psychiatry 161 1992 298 308 (see comments)
49. J.D. Salamone The involvement of nucleus accumbens dopamine in appetitive and aversive motivation Behav. Brain Res. 61 2 1994 117 133
50. D.J. Sanger The search for novel antipsychotics: pharmacological and molecular targets Expert Opin. Ther. Targets 8 6 2004 631 641
51. W. Schultz Getting formal with dopamine and reward Neuron 36 2 2002 241 263
52. P. Shizgal Neural basis of utility estimation Curr. Opin. Neurobiol. 7 2 1997 198 208
53. J.G. Small, M.C. Kolar, and J.J. Kellams Quetiapine in schizophrenia: onset of action within the first week of treatment Curr. Med. Res. Opin. 20 7 2004 1017 1023
54. J.M. Stern, and S.E. Keer Maternal motivation of lactating rats is disrupted by low dosages of haloperidol Behav. Brain Res. 99 2 1999 231 239
55. N. Tarrier, S. Lewis, G. Haddock, R. Bentall, R. Drake, P. Kinderman, D. Kingdon, R. Siddle, J. Everitt, K. Leadley, A. Benn, K. Grazebrook, C. Haley, S. Akhtar, L. Davies, S. Palmer, and G. Dunn Cognitive-behavioural therapy in first-episode and early schizophrenia. 18-month follow-up of a randomised controlled trial Br. J. Psychiatry. 184 2004 231 239
56. J. Tauscher, C. Jones, G. Remington, R.B. Zipursky, and S. Kapur Significant dissociation of brain and plasma kinetics with antipsychotics Mol. Psychiatry 7 3 2002 317 321
57. K. Thompson, J. Kulkarni, and A.A. Sergejew Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses Schizophr. Res. 42 3 2000 241 247
58. T. Van Putten, P.R. May, S.R. Marder, and L.A. Wittmann Subjective response to antipsychotic drugs Arch. Gen. Psychiatry 38 2 1981 187 190
59. L.N. Voruganti, and A.G. Awad Personal evaluation of transitions in treatment (PETiT): a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia Schizophr. Res. 56 1-2 2002 37 46
60. R.M. Wightman, and D.L. Robinson Transient changes in mesolimbic dopamine and their association with 'reward' J. Neurochem. 82 4 2002 721 735
61. R.A. Wise Dopamine, learning and motivation Nat. Rev., Neurosci. 5 6 2004 483 494
62. R.A. Wise, J. Spindler, H. deWit, and G.J. Gerberg Neuroleptic-induced "anhedonia" in rats: pimozide blocks reward quality of food Science 201 4352 1978 262 264
63. A.R. Yung, and P.D. McGorry The prodromal phase of first-episode psychosis: past and current conceptualizations Schizophr. Bull. 22 2 1996 353 370